BioArctic and Eisai presented latest data regarding lecanemab at AD/PD 2021

BioArctic AB and its partner Eisai presented new data on the drug candidate lecanemab (BAN2401) at the 15th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, AD/PD™. The presentations included findings suggesting that lecanemab could be of potential benefit for adults with Down’s syndrome with signs of functional or cognitive deterioration. Preliminary results presented from the ongoing open-label extension of the Phase 2b study in early Alzheimer’s disease continue to support the effect of lecanemab on brain amyloid levels.